Product Pipeline

0 Pre-IND / IND

0 Phase I

0 Phase II

0 Phase III

0 Market Approval / Launched

Posilac

Stage: Market Approval

Indication: -

Type: Therapeutic

Licensee: Union Agener

Wayrilz (rilzabrutinib)

Stage: Market Approval

Indication: -

Type: Therapeutic

EndeavorRX

Stage: Market Approval

Indication: -

Type: Therapeutic

Licensee: Akili

FOR46-001 & FOR46-002

Stage: Phase II

Indication: Oncology

Type: Therapeutic

Licensee: Fortis Therapeutics

STMC-103H

Stage: Phase II

Indication: Autoimmune/Inflammatory

Type: Therapeutic

Licensee: Siolta Therapeutics

VSJ-110 (KSJ compound)

Stage: Phase II

Indication: -

Type: Therapeutic

Licensee: Vanda Pharmaceuticals Inc.

NBIb-1817

Stage: Phase II

Indication: CNS

Type: Therapeutic

Licensee: Voyager Therapeutics (NAS: VYGR)

AER-01

Stage: Phase II

Indication: Respiratory

Type: Therapeutic

Licensee: Aer Therapeutics

GDNF-102

Stage: Phase II

Indication: Metabolic Disease;Neurodegeneration

Type: Therapeutic

Licensee: AskBio/BNB

EPX-100

Stage: Phase II

Indication: Rare/Orphan Disease

Type: Therapeutic

Licensee: Epygenix Therapeutics

SC262

Stage: Phase I

Indication: Hematology

Type: Therapeutic

Licensee: Sana Biotechnology

CRB-601

Stage: Phase I

Indication: -

Type: Therapeutic

Licensee: Corbus Pharmaceuticals, Inc

AB-2100

Stage: Phase I

Indication: Oncology

Type: Therapeutic

Licensee: ArsenalBio

PY314

Stage: Phase I

Indication: -

Type: Therapeutic

Licensee: Foundery Immune Studio, LLC

Biolen

Stage: Phase I

Indication: Oncology

Type: Therapeutic

Licensee: Alessa Therapeutics

AMXI-5001 ATLAS-101

Stage: Phase I

Indication: Oncology

Type: Therapeutic

Licensee: AtlasMedx

DB-OTO

Stage: Phase I

Indication: Otology

Type: Therapeutic

Licensee: Decibel Therapeutics, Inc.

SC291

Stage: Phase I

Indication: -

Type: Therapeutic

Licensee: Sana Biotechnology

AB-1015

Stage: Phase I

Indication: Reproductive Health

Type: Therapeutic

Licensee: ArsenalBio

NRTX-1001

Stage: Phase I

Indication: Neurodegeneration

Type: Therapeutic

Licensee: Neurona Therapeutics

SBT115301

Stage: Phase I

Indication: Autoimmune/Inflammatory

Type: Therapeutic

Licensee: Sonoma Biotherapeutics

SC291

Stage: IND

Indication: -

Type: Therapeutic

Licensee: Sana Biotechnology

MT-101

Stage: IND

Indication: Oncology

Type: Therapeutic

VPO-227 (BPO-27 compound)

Stage: IND

Indication: -

Type: Therapeutic

Licensee: Vanda Pharmaceuticals Inc.

NP001 (Neurodegeneration Product)

Stage: Pre-IND

Indication: Neurodegeneration

Type: Therapeutic

Licensee: Neuvivo, Inc.

HC MNGS PATHOGEN DX

Stage: Regulatory approval/clearance submitted

Indication: -

Type: MedTech Device

Licensee: Delve Bio Inc.